ITGB1 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for targeted disruption of the ITGB1 gene in the A2780 human ovarian carcinoma cell line. This polyclonal pool offers a loss-of-function model to study integrin ??1 function without clonal selection, ensuring robust experimental reproducibility across diverse assay formats.
The A2780 cell line is an adherent epithelial model derived from an untreated ovarian carcinoma patient and is widely recognized for its cisplatin sensitivity. Its epithelial morphology and well-characterized responsiveness to chemotherapeutic agents make it a preferred platform for dissecting mechanisms of adhesion, metastasis, and drug response in ovarian cancer.
ITGB1 encodes the integrin ??1 subunit, which heterodimerizes with ?? integrins such as ITGA5 to form receptors for extracellular matrix ligands including fibronectin (FN1) and collagen type I (COL1A1). Ligand binding induces recruitment of talin-1 (TLN1) and kindlin-2 (FERMT2), leading to FAK (PTK2) autophosphorylation at Y397 and subsequent SRC kinase activation. These events trigger downstream signaling through PIK3CA?CAKT1 and MAPK1/3 (ERK1/2) cascades, as well as RAC1 and RHOA GTPases, which modulate actin dynamics and focal adhesion complex assembly. Transcriptional responses involve JUN and NFKB1, while integrin ??1 signaling upregulates MMP2, MMP9, and cyclin D1 (CCND1), thereby promoting cell proliferation and invasive behavior.
In the A2780 context, ITGB1-mediated adhesion to FN1 and COL1A1-rich matrices is critical for tumor cell survival and cisplatin sensitivity. Disruption of ITGB1 compromises talin?CFAK?CSRC signaling, attenuating AKT and ERK pro-survival pathways. Because ITGB1 is activated by TGFB1, EGF, and HGF and its expression is upregulated by EMT transcription factors SNAI1, ZEB1, and TWIST1, this knockout model provides a defined system to interrogate the contribution of integrin ??1 to epithelial-mesenchymal transition and peritoneal dissemination. The polyclonal nature minimizes clonal artifacts, making it especially suitable for studying heterogeneous responses to matrix cues.
This polyclonal knockout cell product is ideally suited for mechanistic studies of integrin ??1 in ovarian cancer, including adhesion, migration, and invasion assays on ECM-coated surfaces, immunoblotting for ITGB1 and phospho-FAK (Y397), and immunofluorescence visualization of focal adhesion markers such as vinculin. It supports co-immunoprecipitation experiments to probe ITGB1?Ctalin complexes and flow cytometric quantification of surface integrin levels. The knockout model also enables drug sensitivity screening, for example, cisplatin cytotoxicity assays and Annexin V-based apoptosis measurements, to assess the role of ??1 integrins in chemoresistance. Researchers can employ these cells to validate therapeutic targets within the integrin?CFAK?CAKT axis and to explore upstream regulators such as TGFB1 and EMT inducers. For additional technical details or custom research applications, please contact Ascent Research.
